Depression subtypes in predicting antidepressant response: A report from the iSPOT-D trial

American Journal of Psychiatry

Volumn 172, Issue 8, 2015, Pages 743-750

  Arnow, Bruce A ^a   Blasey, Christine ^a   Williams, Leanne M ^a   Palmer, Donna M ^a   Rekshan, William ^a   Schatzberg, Alan F ^a   Etkin, Amit ^a   Kulkarni, Jayashri ^a   Luther, James F ^a   Rush, A John ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLOHEXANOL DERIVATIVE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATYPICAL DEPRESSION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MIXED ANXIETY AND DEPRESSION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SELF REPORT; TREATMENT DURATION; ANXIETY; CLASSIFICATION; CLINICAL TRIAL; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; OUTPATIENT; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929204494     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14020181     Document Type: Article

References (32)

1. Carragher N, Adamson G, Bunting B, et al: Subtypes of depression in a nationally representative sample. J Affect Disord 2009; 113: 88-99
2. Ghaemi SN, Vöhringer PA, Vergne DE: The varieties of depressive experience: diagnosing mood disorders. Psychiatr Clin North Am 2012; 35:73-86
3. Parker G: Through a glass darkly: the disutility of the DSM nosology of depressive disorders. Can J Psychiatry 2006; 51:879-886
4. Uher R, Muthén B, Souery D, et al: Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 2010; 40:1367-1377
5. TrivediMH,Rush AJ,WisniewskiSR, et al:Evaluationofoutcomeswith citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
6. Rush AJ, Trivedi MH, Wisniewski SR, et al: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242
7. Barth J, Munder T, Gerger H, et al: Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013; 10:e1001454
8. Cuijpers P, Sijbrandij M, Koole SL, et al: The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: ameta-analysis ofdirect comparisons. WorldPsychiatry2013; 12:137-148
9. Baumeister H, Parker G: Meta-review of depressive subtyping models. J Affect Disord 2012; 139:126-140
10. Uher R, Dernovsek MZ, Mors O, et al: Melancholic, atypical, and anxiousdepression subtypesandoutcomeof treatmentwith escitalopram and nortriptyline. J Affect Disord 2011; 132:112-120
11. Bobo WV, Chen H, Trivedi MH, et al: Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord 2011; 133:467-476
12. Yang SJ, Stewart R, Kang HJ, et al: Response to antidepressants in major depressive disorder with melancholic features: the CRESCEND study. J Affect Disord 2013; 144:42-50
13. McGrath PJ, Khan AY, Trivedi MH, et al: Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR D report. J Clin Psychiatry 2008; 69:1847-1855
14. Gili M, Roca M, Armengol S, et al: Clinical patterns and treatment outcome in patientswithmelancholic, atypical, and non-melancholic depressions. PLoS ONE 2012; 7:e48200
15. Stewart JW, McGrath PJ, Fava M, et al: Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2010; 13:15-30
16. FavaM, Rush AJ, Alpert JE, et al: Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR D report. Am J Psychiatry 2008; 165:342-351
17. Russell JM, Koran LM, Rush J, et al: Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13:18-27
18. Joyce PR, Mulder RT, Luty SE, et al: A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 2003; 108:20-23
19. Perry PJ: Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39:1-6
20. Joyce PR, Mulder RT, McKenzie JM, et al: Atypical depression, atypical temperament, and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety 2004; 19:180-186
21. Reimherr FW, Wood DR, Byerley B, et al: Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20:70-72
22. Williams LM, Rush AJ, Koslow SH, et al: International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 2011; 12:4
23. Saveanu R, Etkin A, Duchemin AM, et al: The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 2015; 61:1-12
24. SheehanDV,Lecrubier Y, SheehanKH,et al:TheMini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
25. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
26. RushAJ, TrivediMH, IbrahimHM, et al:The 16-ItemQuick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573-583
27. Trivedi MH, Rush AJ, Ibrahim HM, et al: The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73-82
28. Parker G, Hadzi-Pavlovic D: Development and structure of the CORE system, in Melancholia: A Disorder of Movement and Mood. Edited by Parker G, Hadzi-Pavlovic D. Cambridge, UK, Cambridge University Press, 1996, pp 223-236
29. Rush AJ, Gullion CM, Basco MR, et al: The Inventory of Depressive Symptomatology (IDS): psychometric properties. PsycholMed1996; 26:477-486
30. Stewart JW, McGrath PJ, Rabkin JG, et al: Atypical depression: a valid clinical entity? Psychiatr Clin North Am 1993; 16:479-495
31. Fava M, Rush AJ, Alpert JE, et al: What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006; 51:823-835
32. Rush AJ, Wisniewski SR, Warden D, et al: Selecting among secondstep antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65:870-880